Live Breaking News & Updates on Aua Meeting

Stay updated with breaking news from Aua meeting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Enfortumab Vedotin/Pembrolizumab Combo, Maintenance Avelumab Continue as Gold Standards in Metastatic Urothelial Cancer

Lance C. Pagliaro, MD, highlights updated data from the JAVELIN Bladder 100 and EV-103 trials in metastatic urothelial carcinoma, discusses their relevance for navigating the expanding treatment armamentarium for this disease, and outlines several future avenues for research. ....

United States , Mayo Clinic In Rochester , Powlest Sridhar , Lancec Pagliaro , Department Of Oncology , American Urological Association Annual Meeting , Division Of Medical Oncology , Urological Association Annual , Medical Oncology , Mayo Clinic , Science Summit , Enfortumab Vedotin , Asco Annual Meeting , Fda Approval , Aua Meeting , State Of The Science Summit , Mayo Clinic In ,

Link Between PSA Response and Survival Outcomes Supports Use of Darolutamide Plus ADT/Docetaxel as a SOC in mHSPC

Fred Saad, MD, FRCS, expands on the relationship between PSA responses and survival outcomes in the ARASENS trial, explained the use of 0.2 ng/mL as a standard cut off for undetectable PSA within this exploratory analysis, and discussed how this study elucidates future directions for research with triplet regimens in mHSPC. ....

United States , Fred Saad , Raymond Garneau , Montreal Cancer Institute , University Of Montreal Hospital Center , American Urological Association , University Of Montreal , Research Center , Department Of Surgery , Urological Association , Annual Meeting , Montreal Hospital Center , Montreal Cancer , Raymond Garneau Chair , Prostate Cancer , Arasens Trial , Psa Response , Survival Outcomes , Metastatic Hormone Sensitive Prostate Cancer , Triplet Regimens , Aua Meeting ,